Skip to main navigation

Spectrum Pharmaceuticals

Our Company
Products
Development Pipeline
Investor Relations
MEDICAL AFFAIRS
Careers
Contact Us

Quarterly Results

Home
Investor Relations
Financial Information
Quarterly Results

DAY HI:

DAY LOW:

VOLUME:

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Shareholder Tools

Printed Materials
Email Alerts
Download Library
RSS Feeds
Print

Quarterly Results

Show all

2022

Third Quarter

Spectrum Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Form 10-Q

Second Quarter

Spectrum Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Form 10-Q

First Quarter

Spectrum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
Form 10-Q

2021

Fourth Quarter

Spectrum Pharmaceuticals Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Corporate Update
Form 10-K

Third Quarter

Spectrum Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Update
Form 10-Q

Second Quarter

Spectrum Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Update
Form 10-Q

First Quarter

Spectrum Pharmaceuticals Reports First Quarter 2021 Financial Results and Corporate Update
Form 10-Q

2020

Fourth Quarter

Spectrum Pharmaceuticals Reports Fourth Quarter 2020 and Full Year 2020 Financial Results and Pipeline Update
Form 10-K

Third Quarter

Spectrum Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate Update
Form 10-Q

Second Quarter

Spectrum Pharmaceuticals Reports Second Quarter 2020 Financial Results and Corporate Update
Form 10-Q

First Quarter

Spectrum Pharmaceuticals Reports First Quarter 2020 Financial Results and Pipeline Update
Form 10-Q

2019

Fourth Quarter

Spectrum Pharmaceuticals Reports Fourth Quarter 2019 and Full Year 2019 Financial Results and Pipeline Update
Form 10-K

Third Quarter

Spectrum Pharmaceuticals Reports Third Quarter 2019 Financial Results and Pipeline Update
Spectrum Pharmaceuticals 3Q 2019 Earnings Call
Form 10-Q

Second Quarter

Spectrum Pharmaceuticals Reports Second Quarter 2019 Financial Results and Pipeline Update
Spectrum Pharmaceuticals 2Q 2019 Earnings Call
Form 10-Q

First Quarter

Spectrum Pharmaceuticals Reports First Quarter 2019 Financial Results and Pipeline Update
Spectrum Pharmaceuticals 1Q 2019 Earnings Call
Form 10-Q

2018

Fourth Quarter

Spectrum Pharmaceuticals Reports Fourth Quarter 2018 and Full Year 2018 Financial Results and Pipeline Update
Spectrum Pharmaceuticals 4Q 2018 Earnings Call
Form 10-K

Third Quarter

Spectrum Pharmaceuticals Reports Third Quarter 2018 Pipeline Update and Financial Results
Spectrum Pharmaceuticals 3Q 2018 Earnings Call
Form 10-Q

Second Quarter

Spectrum Pharmaceuticals Reports Second Quarter 2018 Financial Results and Pipeline Update
Spectrum Pharmaceuticals 2Q 2018 Earnings Call
Form 10-Q

First Quarter

Spectrum Pharmaceuticals 1Q 2018 Earnings Call
Spectrum Pharmaceuticals Reports First Quarter 2018 Financial Results and Pipeline Update
Form 10-Q

2017

Fourth Quarter

Spectrum Pharmaceuticals 4Q 2017 Earnings Call
Spectrum Pharmaceuticals Reports Fourth Quarter 2017 and Full Year 2017 Financial Results and Pipeline Update
Form 10-K

Third Quarter

Spectrum Pharmaceuticals 3Q 2017 Earnings Call
Spectrum Pharmaceuticals Reports Third Quarter 2017 Financial Results and Pipeline Update
Form 10-Q

Second Quarter

Spectrum Pharmaceuticals 2Q 2017 Earnings Call
Spectrum Pharmaceuticals Reports Second Quarter 2017 Financial Results and Pipeline Update
Form 10-Q

First Quarter

Spectrum Pharmaceuticals Reports First Quarter 2017 Financial Results and Pipeline Update
Spectrum Pharmaceuticals 1Q 2017 Earnings Call
Form 10-Q

2016

Fourth Quarter

Spectrum Pharmaceuticals 4Q 2016 Earnings Call
Spectrum Pharmaceuticals Reports Fourth Quarter 2016 and Full Year 2016 Financial Results and Pipeline Update
Form 10-K

Third Quarter

Spectrum Pharmaceuticals Provides Third Quarter Financial and Pipeline Update
Form 10-Q

Second Quarter

Spectrum Pharmaceuticals Reports Second Quarter 2016 Financial Results and Pipeline Update
Form 10-Q
Spectrum Pharmaceuticals 2Q 2016 Earnings Call

First Quarter

Spectrum Pharmaceuticals Reports First Quarter 2016 Financial Results and Pipeline Update
Form 10-Q
Spectrum Pharmaceuticals 1Q 2016 Earnings Call

2015

Fourth Quarter

Spectrum Pharmaceuticals Reports Fourth Quarter 2015 and Full Year 2015 Financial Results and Pipeline Update
Form 10-K
Fourth Quarter 2015 Financial Results Conference Call

Third Quarter

Spectrum Pharmaceuticals Reports Third Quarter 2015 Financial Results and Pipeline Update
Form 10-Q
Third Quarter 2015 Financial Results Conference Call

Second Quarter

Spectrum Pharmaceuticals Reports Second Quarter 2015 Financial Results and Pipeline Update
Form 10-Q
Second Quarter 2015 Financial Results Conference Call

First Quarter

Spectrum Pharmaceuticals Reports Continued Advancement of Robust, Late-Stage Pipeline and First Quarter 2015 Financial Results
Form 10-Q

2014

Fourth Quarter

Spectrum Pharmaceuticals Reports Robust Clinical Data and Strong 2014 Financial Results
Form 10-K

Third Quarter

Spectrum Pharmaceuticals Reports Strong Product Sales for the Third Quarter 2014; Sales of $47.9 Million up 15.6% Over Last Year
Form 10-Q

Second Quarter

Spectrum Pharmaceuticals Reports 45% Sales Growth in the Second Quarter, Launches Fifth Product and Moves Closer to a Decision on a Potential Blockbuster
Form 10-Q

First Quarter

Spectrum Pharmaceuticals Reports Financial Results for First Quarter 2014
Form 10-Q

2013

Fourth Quarter

Spectrum Pharmaceuticals Reports Fourth and Full Year 2013 Financial Results
Form 10-K

Third Quarter

Spectrum Pharmaceuticals Reports Financial Results for Third Quarter 2013
Form 10-Q

Second Quarter

Spectrum Pharmaceuticals Reports Financial Results for Second Quarter 2013
Form 10-Q

First Quarter

Spectrum Pharmaceuticals Reports Financial Results for First Quarter 2013
Form 10-Q

2012

Fourth Quarter

Spectrum Pharmaceuticals Reports Record Revenues, Profits, and Cash Generated from Operations for the Twelve-Month Period Ended December 31, 2012
Form 10-K

Third Quarter

INSERTING and REPLACING Spectrum Pharmaceuticals Reports Strong Revenues and Profits for Third Quarter; Revenues of $69 million up 35% over last year and GAAP Diluted EPS of $0.33 and Non-GAAP Diluted EPS of $0.42
Form 10-Q

Second Quarter

Spectrum Pharmaceuticals Reports Record Revenues and Strong Profits for Second Quarter; Revenues of $68.7 Million up 51.5% over Last Year and Strong non-GAAP EPS of $0.37, up 48% over Last Year
Form 10-Q

First Quarter

Spectrum Pharmaceuticals Reports Record Revenues and Profits for First Quarter of 2012
Form 10-Q

2011

Fourth Quarter

Spectrum Pharmaceuticals Reports Record Revenues, Profits, and Cash Generated from Operations for the Twelve-Month Period Ended December 31, 2011
Form 10-K

Third Quarter

Spectrum Pharmaceuticals, Inc. Reports Strongest Financial Position in Company History: Record Revenues, Profits, and Cash Generated from Operations for the Three- and Nine-Month Periods Ended September 30, 2011
Form 10-Q

Second Quarter

Spectrum Pharmaceuticals Generates Cash from Operations, Reports Third Consecutive Profitable Quarter, and Record Revenue for the Three- and Six-Month Periods Ended June 30, 2011; Strongest Financial Position in Company History
Form 10-Q

First Quarter

Spectrum Pharmaceuticals Reports Record Profit and Record Revenue for First Quarter 2011, a Four-Fold Revenue Increase over First Quarter 2010
Form 10-Q

2010

Fourth Quarter

Spectrum Pharmaceuticals Reports Profitable Fourth Quarter and Record Revenue Growth for 2010
Form 10-K

Third Quarter

Spectrum Pharmaceuticals Announces Third Quarter 2010 Financial and Operating Results
Form 10-Q

Second Quarter

Spectrum Pharmaceuticals Announces Second Quarter 2010 Corporate Update

First Quarter

Spectrum Pharmaceuticals Announces First Quarter 2010 Corporate Update
Form 10-Q

2009

Fourth Quarter

Spectrum Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2009 Corporate Update
Form 10-K

Third Quarter

Spectrum Pharmaceuticals Announces Third Quarter 2009 Corporate Update; ZEVALIN® Sales up 80% over Third Quarter 2008
Form 10-Q

Second Quarter

Spectrum Pharmaceuticals Announces Second Quarter 2009 Corporate Update
Form 10-Q

First Quarter

Spectrum Pharmaceuticals Announces First Quarter 2009 Corporate Update and Pipeline Review
Form 10-Q

2008

Fourth Quarter

Spectrum Pharmaceuticals Announces Fiscal Year 2008 Corporate Update and Pipeline Review
Form 10-K

Third Quarter

Spectrum Pharmaceuticals Announces Third Quarter Corporate Update and Pipeline Review
Form 10-Q

Second Quarter

Spectrum Pharmaceuticals Announces Second Quarter 2008 Corporate Update and Pipeline Review Conference Call
Form 10-Q

First Quarter

Spectrum Pharmaceuticals Announces First Quarter 2008 Financial Results and Pipeline Update
Form 10-Q

2007

Fourth Quarter

Spectrum Pharmaceuticals Announces 2007 Financial Results and Pipeline Update
Form 10-K

Third Quarter

Spectrum Pharmaceuticals Announces Third Quarter 2007 Financial Results and Pipeline Update
Form 10-Q

Second Quarter

Spectrum Pharmaceuticals Announces Second Quarter 2007 Financial Results and Pipeline Update
Form 10-Q

First Quarter

Form 10-Q

2006

Fourth Quarter

Form 10-K/A

Third Quarter

Form 10-Q

Second Quarter

Form 10-Q

First Quarter

Form 10-Q

Our Company

Company Philosophy
Corporate Compliance
Management
Responsibility
Board of Directors

Products

ROLVEDON™ (eflapegrastim-xnst)

Development Pipeline

Pipeline
Poziotinib
Clinical Trials
Glossary

Investor Relations

Press Releases
Events and Presentations
Corporate Governance
Annual Report and Proxy Information
Financial Information
Stock Information
Investor FAQs

Medical Affairs

Medical Information
Expanded Access Program

Careers

Contact Us

This Web site contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on the beliefs of the Company's management as well as assumptions made by and information currently available to the Company's management. Readers should not put undue reliance on these forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Spectrum Pharmaceuticals, Inc.'s actual results may differ materially from the results projected in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed in the Company's most recent Form 10-K and 10-Qs. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this filing except as required by law.

ROLVEDON is a trademark of Spectrum Pharmaceuticals, Inc.
© 2023 Spectrum Pharmaceuticals, Inc. All Rights Reserved.
PP-ALL-00-0054

Site Map
Privacy Policy
Terms of Use
Contact Us